Physician profile
Ryan E Gegg
NPI 1710241054
$10,569.82
in general payments reported to CMS, 2019-2025
20 companies · $2,930 in 2025
The $2,930 reported for 2025 was more than what 93% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $491 · 2021: $317 · 2022: $1,764 · 2023: $1,908 · 2024: $2,452 · 2025: $2,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,519 · Travel and Lodging: $718 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,518.60 |
| Travel and Lodging | $718.01 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $4,848.42 | 2022-2025 | Inspire |
| Medtronic, INC. | $2,471.81 | 2023-2025 | Propel, Fusion, Nuvent |
| Aerin Medical INC. | $847.58 | 2019-2025 | |
| Intersect Ent, INC. | $606.98 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $335.94 | 2020-2025 | Dupixent |
| Genzyme Corporation | $323.98 | 2021-2025 | |
| Integra Lifesciences Corporation | $314.57 | 2024 | Trudi Probe, Inspira Air, Acclarent Aera |
| Optinose US, INC. | $292.38 | 2019-2022 | |
| Acclarent, INC | $153.15 | 2019-2022 | |
| Neurent Medical Limited | $114.69 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Stryker Corporation | $49.41 | 2019-2024 | Scopis Ent |
| Alk-Abello, INC | $41.21 | 2020-2023 | Grastek, Odactra, Ragwitek |
| Smith+Nephew, INC. | $21.40 | 2025 | Coblation, Ent Sinus, Halo |
| Ars Pharmaceuticals Operations, INC. | $21.29 | 2025 | Neffy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.02 | 2024 | Tavneos |
| Medtronic USA, INC. | $17.89 | 2019 | |
| Hikma Pharmaceuticals USA | $14.91 | 2023 | Ryaltris |
| Arbor Pharmaceuticals, INC. | $13.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $8.99 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gegg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.